133 related articles for article (PubMed ID: 29088720)
1. Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein.
Morillon YM; Hammond SA; Durham NM; Schlom J; Greiner JW
Oncotarget; 2017 Sep; 8(43):73469-73482. PubMed ID: 29088720
[TBL] [Abstract][Full Text] [Related]
2. A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
Leyland R; Watkins A; Mulgrew KA; Holoweckyj N; Bamber L; Tigue NJ; Offer E; Andrews J; Yan L; Mullins S; Oberst MD; Coates Ulrichsen J; Leinster DA; McGlinchey K; Young L; Morrow M; Hammond SA; Mallinder P; Herath A; Leow CC; Wilkinson RW; Stewart R
Clin Cancer Res; 2017 Jul; 23(13):3416-3427. PubMed ID: 28069723
[No Abstract] [Full Text] [Related]
3. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
4. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
Hodge JW; Higgins J; Schlom J
Vaccine; 2009 Jul; 27(33):4475-82. PubMed ID: 19450631
[TBL] [Abstract][Full Text] [Related]
5. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
[TBL] [Abstract][Full Text] [Related]
6. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
7. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
[TBL] [Abstract][Full Text] [Related]
8. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
9. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
[TBL] [Abstract][Full Text] [Related]
11. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules.
Briones J; Timmerman JM; Panicalli DL; Levy R
J Natl Cancer Inst; 2003 Apr; 95(7):548-55. PubMed ID: 12671023
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2004 Feb; 10(3):1090-9. PubMed ID: 14871989
[TBL] [Abstract][Full Text] [Related]
13. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
Greiner JW; Zeytin H; Anver MR; Schlom J
Cancer Res; 2002 Dec; 62(23):6944-51. PubMed ID: 12460911
[TBL] [Abstract][Full Text] [Related]
14. Technology evaluation: CEA-TRICOM, Therion Biologics Corp.
Morse MA
Curr Opin Mol Ther; 2001 Aug; 3(4):407-12. PubMed ID: 11525565
[TBL] [Abstract][Full Text] [Related]
15. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy.
Slavin-Chiorini DC; Catalfamo M; Kudo-Saito C; Hodge JW; Schlom J; Sabzevari H
Cancer Gene Ther; 2004 Oct; 11(10):665-80. PubMed ID: 15354200
[TBL] [Abstract][Full Text] [Related]
16. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
[TBL] [Abstract][Full Text] [Related]
17. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.
Hodge JW; Rad AN; Grosenbach DW; Sabzevari H; Yafal AG; Gritz L; Schlom J
J Natl Cancer Inst; 2000 Aug; 92(15):1228-39. PubMed ID: 10922408
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific crosslinking of GITR as costimulation for immunotherapy.
Burckhart T; Thiel M; Nishikawa H; Wüest T; Müller D; Zippelius A; Ritter G; Old L; Shiku H; Renner C
J Immunother; 2010; 33(9):925-34. PubMed ID: 20948444
[TBL] [Abstract][Full Text] [Related]
19. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
Zhu M; Terasawa H; Gulley J; Panicali D; Arlen P; Schlom J; Tsang KY
Cancer Res; 2001 May; 61(9):3725-34. PubMed ID: 11325845
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity.
Kudo-Saito C; Garnett CT; Wansley EK; Schlom J; Hodge JW
Cancer Immunol Immunother; 2007 Dec; 56(12):1897-910. PubMed ID: 17503041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
